DK3604339T3 - Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme - Google Patents

Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme Download PDF

Info

Publication number
DK3604339T3
DK3604339T3 DK19192973.6T DK19192973T DK3604339T3 DK 3604339 T3 DK3604339 T3 DK 3604339T3 DK 19192973 T DK19192973 T DK 19192973T DK 3604339 T3 DK3604339 T3 DK 3604339T3
Authority
DK
Denmark
Prior art keywords
protein
methods
same
antibodies against
therapeutic antibodies
Prior art date
Application number
DK19192973.6T
Other languages
English (en)
Inventor
Thomas J Kipps
Ii George F Widhopf
Bing Cui
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46507696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3604339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK3604339T3 publication Critical patent/DK3604339T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK19192973.6T 2011-01-14 2012-01-13 Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme DK3604339T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161433043P 2011-01-14 2011-01-14
EP17167174.6A EP3252076B1 (en) 2011-01-14 2012-01-13 Diagnostic use of antibodies against ror-1 protein

Publications (1)

Publication Number Publication Date
DK3604339T3 true DK3604339T3 (da) 2021-04-12

Family

ID=46507696

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17167174T DK3252076T3 (da) 2011-01-14 2012-01-13 Diagnostisk anvendelse af antistoffer mod ror-1-protein
DK19192973.6T DK3604339T3 (da) 2011-01-14 2012-01-13 Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
DK12734733.4T DK2663579T3 (da) 2011-01-14 2012-01-13 Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17167174T DK3252076T3 (da) 2011-01-14 2012-01-13 Diagnostisk anvendelse af antistoffer mod ror-1-protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12734733.4T DK2663579T3 (da) 2011-01-14 2012-01-13 Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse deraf

Country Status (9)

Country Link
US (7) US9217040B2 (da)
EP (4) EP2663579B1 (da)
CA (3) CA2858350A1 (da)
DK (3) DK3252076T3 (da)
ES (3) ES2865068T3 (da)
HU (2) HUE035281T2 (da)
PL (2) PL2663579T3 (da)
PT (2) PT3604339T (da)
WO (1) WO2012097313A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635316T3 (es) 2009-12-18 2017-10-03 Kancera Ab Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN104662044B (zh) * 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
ES2876925T3 (es) * 2014-07-29 2021-11-15 Cellectis Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
ES2777305T3 (es) 2014-09-04 2020-08-04 Cellectis Receptores de antígeno quiméricos específicos de la glicoproteína trofoblástica (5T4, TPBG) para inmunoterapia contra el cáncer
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20160132534A (ko) 2015-05-11 2016-11-21 경북대학교병원 ＲＯＲα 활성조절제를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2018524284A (ja) * 2015-05-18 2018-08-30 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１抗体
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2016263513A1 (en) 2015-05-20 2017-11-23 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
KR20180069067A (ko) 2015-10-30 2018-06-22 엔비이-테라퓨틱스 아게 안티-ror1 항체
JP7000660B2 (ja) 2016-01-20 2022-02-04 ザ スクリプス リサーチ インスティテュート Ｒｏｒ１抗体組成物及び関連の方法
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20190058509A (ko) 2016-10-07 2019-05-29 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20200062161A (ko) 2017-06-23 2020-06-03 벨로스바이오 인코포레이티드 Ror1 항체 면역접합체
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
CN111133002B (zh) 2017-08-07 2024-05-24 恩比伊治疗股份公司 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
US20210106618A1 (en) 2017-09-06 2021-04-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US10905750B2 (en) 2017-11-10 2021-02-02 Donald J. Davidson GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
CN112041335A (zh) 2018-02-26 2020-12-04 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的组合物和方法
US11883492B2 (en) * 2018-03-09 2024-01-30 The Regents Of The University Of California Combination treatment of chemoresistant cancers
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20220323598A1 (en) * 2018-08-01 2022-10-13 National University Corporation Tokai National Higher Education And Research System Anti-ror1 monoclonal antibody, functional fragment thereof, gene, drug delivery composition, and pharmaceutical composition
AU2021334677A1 (en) * 2020-08-24 2023-03-02 Epimab Biotherapeutics (Hk) Limited Anti-ROR1 antibodies and related bispecific binding proteins
WO2022188652A1 (zh) 2021-03-09 2022-09-15 四川科伦博泰生物医药股份有限公司 Ror1结合蛋白及其用途
JP2024521629A (ja) 2021-06-02 2024-06-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物コンジュゲート、及びその調製方法及びその使用
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN113980133B (zh) * 2021-10-29 2022-09-13 叶鑫淼 抗体及其在抗肿瘤中的应用
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
US5169836A (en) 1988-11-10 1992-12-08 Trustees Of The University Of Penna. Inhibitors of platelet binding
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
EP0598998B1 (en) 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
ATE208403T1 (de) 1995-05-26 2001-11-15 Merck Patent Gmbh Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
CA2223577A1 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997043416A1 (en) 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2352082T3 (es) 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
US7041490B1 (en) 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
TR200100705T2 (tr) 1998-06-26 2001-10-22 Iowa State University Research Foundation, Inc. Bitkilerde enzim ve asetil'in değiştirilmesi için yöntemler.
ES2246093T3 (es) 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
AU777342B2 (en) 1999-03-11 2004-10-14 Arborgen Llc Compositions and methods for the modification of gene transcription
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6753314B1 (en) 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
AU763162B2 (en) 1999-04-13 2003-07-17 Wilex Ag Diagnostic and therapeutic use of antibodies against the urokinase receptor
US20060242729A1 (en) 1999-07-30 2006-10-26 Cahoon Edgar B Polynucleotides encoding proteins involved in plant metabolism
GB9918788D0 (en) 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
US20020034784A1 (en) 1999-10-27 2002-03-21 John Bertin Novel molecules of the card-related protein family and uses thereof
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
US20030092091A1 (en) 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
US6833447B1 (en) 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20030071861A (ko) 2001-01-26 2003-09-06 인히비텍스, 인코포레이티드 Ｃｌｆａ 단백질에 대한 단일 클론성 항체 및 감염의 치료또는 예방에 있어서의 사용 방법
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002302919A1 (en) 2001-02-22 2002-10-03 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7282336B2 (en) 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
KR100464926B1 (ko) 2001-09-14 2005-01-05 한국과학기술연구원 ＨＩＶ-1 ｇｐ41의 Ｎ-말단에 특이적으로 결합하는 항체
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1495055B1 (en) 2002-04-18 2013-08-14 Genencor International, Inc. Production of functional antibodies in filamentous fungi
GB0210783D0 (en) 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US8344211B2 (en) 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
US7205450B2 (en) 2003-10-08 2007-04-17 The Regents Of The University Of California DMI1 gene encodes a protein that is required for the early steps of bacterial and fungal symbioses
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
US7608700B2 (en) 2004-03-08 2009-10-27 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
EP1735461A4 (en) 2004-04-06 2008-10-29 Univ California ORPHANIC RECEPTOR TYROSINE KINASE AS A TARGET IN BREAST CANCER
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
JP4890449B2 (ja) 2004-05-25 2012-03-07 アテニュオン， エルエルシー 下流ｕＰＡＲ相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子（ｕＰＡ）とそのレセプター（ｕＰＡＲ）との複合体に結合するリガンド：診断または治療における同定および使用
US7629444B1 (en) 2004-06-15 2009-12-08 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus bovienii strain Xs85831 and uses thereof
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
ATE531733T1 (de) 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
AU2006220772A1 (en) 2005-03-04 2006-09-14 Verenium Corporation Nucleic acids and proteins and methods for making and using them
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
US7723110B2 (en) 2005-06-17 2010-05-25 Arborgen, Llc Plant cell signaling genes
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
EP1948680A4 (en) * 2005-10-28 2010-01-13 Univ California METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
AU2006315037C1 (en) 2005-11-18 2013-05-02 Ichnos Sciences SA Anti-alpha2 integrin antibodies and their uses
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
EP2527370A1 (en) 2005-12-21 2012-11-28 Amgen Research (Munich) GmbH Compounds having resistance to soluble CEA
AU2007207764B2 (en) 2006-01-12 2012-06-07 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US7589257B2 (en) 2006-02-09 2009-09-15 Pioneer Hi-Bred International Inc. Genes for enhancing nitrogen utilization efficiency in crop plants
CA2637665A1 (en) 2006-02-10 2007-08-23 Monsanto Technology Llc Identification and use of target genes for control of the plant parasitic nematodes heterodera glycines
JP2009532336A (ja) 2006-03-06 2009-09-10 メディミューン，エルエルシー ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
WO2007109742A2 (en) 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
WO2007109747A2 (en) 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US7727525B2 (en) 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
ES2549128T3 (es) 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2047252B1 (en) 2006-06-22 2013-01-23 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
EP2316855B1 (en) 2006-07-12 2016-09-21 Gene Techno Science Co., Ltd. Antihuman alpha-9 integrin antibody and use of the same
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
EP2610267A1 (en) 2006-12-18 2013-07-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
AR065271A1 (es) 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
US8192740B2 (en) 2007-02-27 2012-06-05 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
CA2676049C (en) 2007-03-01 2018-04-10 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN101646457B (zh) 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
EP3187507A1 (en) 2007-04-23 2017-07-05 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
ATE540313T1 (de) 2007-05-03 2012-01-15 Regeneron Pharma Identifizierung von keimbahnfähigen embryonischen stammzellen
EP2185199A4 (en) 2007-07-31 2010-09-08 Merck Sharp & Dohme SPECIFIC ANTIBODIES OF IGF-1R USEFUL IN THE DETECTION AND DIAGNOSIS OF CELL PROLIFERATION DISORDERS
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP2200634B1 (en) 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US8309323B2 (en) 2007-11-13 2012-11-13 Synthetic Genomics, Inc. Dimethyloctane as an advanced biofuel
EP2220122A2 (en) 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
AU2009251767A1 (en) 2008-02-28 2009-12-03 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic metabolism genes and enzymes from Alicyclobacillus acidocaldarius and related organisms
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
EP2272872A4 (en) 2008-03-21 2011-04-06 Hayashibara Biochem Lab MONOCLONAL ANTIBODIES SPECIFICALLY RECOGNIZING THE ALPHA 8 SUBTYPE OF THE HUMAN ALPHA INTERFERON AND ASSOCIATED MUTANT PROTEIN
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
NZ590330A (en) 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
BRPI0912898B1 (pt) 2008-08-18 2022-04-12 Evogene Ltd Método para aumentar a eficiência de uso do nitrogênio e/ou tolerância à deficiência de nitrogênio de uma planta
AU2009312532B2 (en) 2008-11-06 2013-05-16 Ichnos Sciences SA Treatment with anti-alpha2 integrin antibodies
TW201031421A (en) 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
BRPI1013688A8 (pt) 2009-03-05 2017-02-14 Abbott Lab Proteínas de ligação de il-17.
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US8753631B2 (en) 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2780713A1 (en) 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
CN102753580A (zh) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 抗egfr抗体及其用途
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
ES2635316T3 (es) 2009-12-18 2017-10-03 Kancera Ab Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
EP2933269A1 (en) 2009-12-18 2015-10-21 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
WO2011091412A1 (en) 2010-01-25 2011-07-28 Alere Scarborough, Inc. A25 bacteriophage lysin
AU2011209713B2 (en) 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
US9085623B2 (en) 2010-02-11 2015-07-21 Alexion Pharmaceuticals, Inc. Therapeutic methods using anti-CD200 antibodies
EP3590966A1 (en) 2010-02-23 2020-01-08 Sanofi Anti-alpha2 integrin antibodies and their uses
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
CN102190728B (zh) 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
WO2011123859A1 (en) 2010-04-02 2011-10-06 Skyfire Labs, Inc. Assisted hybrid mobile browser
EP2563393B1 (en) 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
CN101928347B (zh) 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
AU2011261270A1 (en) 2010-06-03 2012-12-13 Abraxis Bioscience, Llc Peripheral blood SPARC antibodies and uses thereof
PT2580240T (pt) 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
KR101930179B1 (ko) 2010-08-27 2018-12-17 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
US20130302346A1 (en) 2010-11-24 2013-11-14 Lexicon Pharmaceuticals, Inc. Antibodies that bind notum pectinacetylesterase
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
PE20141060A1 (es) 2010-12-21 2014-09-26 Abbvie Inc Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2691156A1 (en) 2011-03-30 2014-02-05 Boehringer Ingelheim International GmbH Anticoagulant antidotes
JP6139509B2 (ja) 2011-04-21 2017-05-31 ザ ロックフェラー ユニバーシティ グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
CA2844289C (en) 2011-08-12 2020-01-14 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CA2854720C (en) 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
EA031948B1 (ru) 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
CA2856873A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
US10464079B2 (en) 2011-11-28 2019-11-05 Xiamen Solex High-Tech Industries Co., Ltd. Concealed top cover-type shower head
EP2617319A1 (en) 2012-01-17 2013-07-24 Braun GmbH Head portion and handle portion of an oral care device
ES2743203T3 (es) 2012-02-06 2020-02-18 Inhibrx Inc Anticuerpos CD47 y métodos de uso de los mismos
ES2800426T3 (es) 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
DK2877576T3 (da) 2012-07-24 2019-08-12 Bp Corp North America Inc Xyloseisomeraser og anvendelser deraf
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
RU2725520C2 (ru) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害

Also Published As

Publication number Publication date
US20160097776A1 (en) 2016-04-07
ES2634098T3 (es) 2017-09-26
DK2663579T3 (da) 2017-07-31
PT2663579T (pt) 2017-07-28
US10900973B2 (en) 2021-01-26
US9523695B2 (en) 2016-12-20
EP2663579B1 (en) 2017-04-26
ES2758533T3 (es) 2020-05-05
US11536727B2 (en) 2022-12-27
US10627409B2 (en) 2020-04-21
EP3885366A3 (en) 2021-12-29
CA3027071A1 (en) 2013-07-19
PL3604339T3 (pl) 2021-12-27
WO2012097313A2 (en) 2012-07-19
EP3252076B1 (en) 2019-09-04
EP2663579A2 (en) 2013-11-20
EP3604339B1 (en) 2021-03-10
US9217040B2 (en) 2015-12-22
PL2663579T3 (pl) 2017-09-29
EP2663579A4 (en) 2014-09-17
US20170248585A1 (en) 2017-08-31
US20230341412A1 (en) 2023-10-26
US20200309785A1 (en) 2020-10-01
HUE053720T2 (hu) 2021-07-28
US20180348232A1 (en) 2018-12-06
ES2865068T3 (es) 2021-10-14
CA2981662C (en) 2019-02-05
US20210208158A1 (en) 2021-07-08
EP3252076A1 (en) 2017-12-06
CA2858350A1 (en) 2013-07-19
WO2012097313A3 (en) 2013-01-10
EP3885366A2 (en) 2021-09-29
DK3252076T3 (da) 2019-12-02
US9933434B2 (en) 2018-04-03
HUE035281T2 (en) 2018-05-02
PT3604339T (pt) 2021-04-13
CA2981662A1 (en) 2013-07-19
US20130273073A1 (en) 2013-10-17
EP3604339A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
DK3604339T3 (da) Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
HK1211030A1 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same iap
DK3736292T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK2710033T3 (da) Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2785375T3 (da) Anti-pd-l1-antistoffer og anvendelser deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK3744835T3 (da) Dna modificerende fusionsproteiner og metoder til anvendelse deraf
DK2714135T3 (da) Medikamentadministrationsanordning og fremgangsmåde til styring af anordningen
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
DK2917229T3 (da) Antistoffer og fragmenter, der er mod alfa-3-domænerne af hla-g-protein, fremgangsmåder og midler til deres forberedelse, og anvendelsen deraf
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde